Welcome to our dedicated page for Biomx SEC filings (Ticker: PHGE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BiomX Inc. (PHGE) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including Form 8-K current reports and other key documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on BiomX’s clinical-stage phage therapy programs, corporate actions and financing arrangements, and they complement the company’s press releases for investors researching PHGE stock.
BiomX’s recent Form 8-K filings describe several material events. These include the initiation and terms of a private placement of Series Y Convertible Preferred Stock and related warrants, with details on dividend rights, conversion mechanics, exercise prices, registration rights and stockholder approval requirements. Other 8-Ks outline the authorization and implementation of a one-for-nineteen reverse stock split of the common stock listed on NYSE American under the symbol PHGE, along with proportional adjustments to equity awards, warrants and convertible preferred stock.
Filings also document significant developments in BiomX’s clinical and operational landscape. The company has reported an FDA clinical hold on the U.S. portion of its BX004 Phase 2b study, subsequent FDA follow-up questions on a third-party nebulizer device, and the eventual discontinuation of the BX004 Phase 2b trial after internal review and Data Monitoring Committee recommendations. Additional 8-Ks describe cost-cutting measures, workforce reductions, and the decision by the board of BiomX Ltd., an Israeli subsidiary, to approve and authorize the filing of an application to commence insolvency proceedings. Lease termination terms for Adaptive Phage Therapeutics, LLC, a wholly owned subsidiary, are also set out in detail.
Through this page, users can review how BiomX reports on its BX011 and BX211 phage programs for diabetic foot disease, its capital structure changes, and board and governance matters. Stock Titan enhances these filings with AI-powered summaries that highlight key terms, clinical implications and capital market impacts, helping readers quickly understand complex items such as preferred stock designations, warrant adjustments, clinical trial disclosures and strategic alternatives discussed in BiomX’s SEC reports.
BiomX Inc. reported that its Israeli subsidiary, BiomX Ltd., will seek insolvency proceedings under the Israeli Insolvency and Financial Regulation law 5778-2018. This follows the earlier discontinuation of a Phase 2b clinical study after the company concluded that the timelines and resources required for an alternative dosing strategy exceeded its available resources.
In light of these limited financial resources, the BiomX Ltd. board authorized filing the insolvency application on December 11, 2025. BiomX Inc. states that it is evaluating strategic options and continues to own its BX011 program for diabetic foot infections, which is being conducted by its other subsidiary, Adaptive Phage Therapeutics, Inc.
BiomX Inc. reported that it is discontinuing its ongoing Phase 2b clinical trial of BX004 in cystic fibrosis patients with chronic Pseudomonas aeruginosa infections. Management concluded that the timelines and resources needed to pursue an alternative dosing strategy recommended by the independent Data Monitoring Committee were beyond the company’s available resources.
BiomX is implementing cost-cutting measures, including a significant reduction of its workforce, and plans to concentrate its efforts on advancing its bacteriophage-based therapeutics, particularly BX011 for diabetic foot infections, if sufficient financial and other resources are available. The company is also reviewing other strategic alternatives while noting that these plans involve forward-looking statements subject to substantial risks and uncertainties.
BiomX Inc. (PHGE) reported an update on its Phase 2b study of BX004 for treating cystic fibrosis. The U.S. FDA is continuing its clinical hold while it evaluates a third-party nebulizer device used to deliver BX004, and BiomX is working with the device manufacturer to answer follow-up FDA information requests in order to lift the hold. The company believes the remaining items are readily addressable and expects U.S. enrollment to resume once this process is complete and subject to available financing. An independent Data Monitoring Committee completed a safety review of the study, including participants who experienced adverse events, and recommended the trial continue with an adjusted dosing regimen. BiomX is updating the protocol accordingly and, depending on financial resources and other factors, now expects topline results in the second quarter of 2026.
BiomX Inc. announced that its board approved a one-for-nineteen (1:19) reverse stock split of its common stock. The split is scheduled to take effect at 12:01 a.m. Eastern Time on November 25, 2025, with BiomX shares expected to begin trading on the NYSE American on a split-adjusted basis that same day. Every nineteen existing shares will be combined into one new share, without changing the total number of shares the company is authorized to issue or the par value or rights of the common stock. Stockholders will not receive fractional shares; instead, positions will be rounded up to the nearest whole share, and outstanding equity awards, warrants, convertible preferred stock and plan share limits will be adjusted proportionally.
BiomX (PHGE) reported Q3 2025 results marked by ongoing R&D progress alongside tight liquidity. The company posted a net loss of $9.166M and an operating loss of $8.536M. R&D expenses, net, were $6.122M (down 16% year over year), and G&A expenses were $2.414M (down 25%).
Cash resources remain limited. Cash, cash equivalents and restricted cash were $8.069M at September 30, 2025. For the nine months, cash used in operating activities totaled $22.004M, partly offset by $11.938M of financing inflows, including February 2025 capital actions and modest ATM sales. Management states current funds are sufficient into Q1 2026 and notes substantial doubt about the ability to continue as a going concern.
On the pipeline, the Phase 2b CF study of BX004 continues in Europe, while the FDA placed a clinical hold in August 2025 related to the third‑party nebulizer device; no issues were raised regarding BX004 itself. BiomX believes it has addressed FDA device queries and expects topline results in Q1 2026. The company also reported positive Phase 2 results in DFO (BX211) and plans to advance BX011 in DFI subject to resources. Shares outstanding were 29,006,165 as of November 11, 2025.
BiomX Inc. (PHGE) filed an 8-K stating it furnished a press release announcing financial results for the third quarter ended September 30, 2025. The release was provided under Item 2.02 and attached as Exhibit 99.1. This is a standard disclosure to make the company’s quarterly results announcement part of the public record.
BiomX Inc. (PHGE) reported voting results from its 2025 Annual Meeting. Stockholders approved authorizing the Board to amend the certificate of incorporation to effect a reverse stock split of the outstanding Common Stock at any ratio between at least 1-for-5 and less than 1-for-20, with 13,641,280 votes for, 383,712 against, and 71,143 abstaining.
Three Class II directors—Susan Blum, Dr. Jesse Goodman, and Gregory Merril—were elected to serve until the 2028 annual meeting. Stockholders also ratified Kesselman & Kesselman, a member firm of PwC International Limited, as the independent registered public accounting firm for fiscal 2025 (14,050,210 for; 25,633 against; 20,294 abstaining). A proposal to adjourn the meeting was not called.
BiomX Inc. (PHGE) updated its Phase 2b BX004 program for cystic fibrosis. The FDA sent additional, narrow questions focused solely on the third‑party nebulizer used to deliver BX004, with no concerns raised about the drug itself. BiomX believes it has fully addressed these device-related queries.
Enrollment and dosing in the European portion of the study are proceeding ahead of plan, and topline results remain on track for the first quarter of 2026. The FDA also provided new written feedback recognizing the unmet need in chronic Pseudomonas aeruginosa infection and outlined potential development pathways, including refined inclusion criteria and approaches to enrich patient populations for a potential Phase 3 program.
BiomX plans to incorporate the FDA’s recommendations, as appropriate and subject to future study data, regulatory alignment, and resources, and anticipates an End-of-Phase 2 meeting after completion and review of the Phase 2b results.
BiomX Inc. will hold its 2025 annual meeting virtually on October 16, 2025 at 8:00 a.m. Eastern Time for holders of record as of August 22, 2025. Key proposals include authorization for the Board to implement a reverse stock split of common stock at a ratio between 1-for-5 and less than 1-for-20 to be effected by October 16, 2026, ratification of Kesselman & Kesselman (a PwC member firm) as independent auditors for fiscal 2025, and approval to adjourn the meeting if necessary to continue soliciting votes. The proxy describes voting methods (written notice, later-dated proxy online/telephone, or electronic voting during the meeting), lists Board nominees and committee structure, summarizes an insider trading policy with specific prohibited transactions, and discloses certain audit fees and significant stockholders including two holders each with 9.9% stakes and Nantahala Capital Management at 9.9%.
BiomX Inc. reports that the U.S. Food and Drug Administration has placed a clinical hold on the U.S. portion of its Phase 2b study of BX004 for treating cystic fibrosis. The FDA is reviewing data BiomX submitted on a third-party nebulizer device used to deliver BX004 and, in its notification, did not raise concerns about BX004 itself. Following the notification, BiomX provided additional requested data to the FDA, and patient screening and enrollment in the United States have been paused.
In Europe, all components of the third-party nebulizer are CE marked and have been deemed to meet applicable regulatory requirements. The Phase 2b study in the European Union has been approved, and enrollment and dosing of patients are continuing according to the study protocol.